Thrombotic Microangiopathy post Simultaneous Pancreas-Kidney (SPK) transplant: a challenging scenario (TTS 2026) - Sep 17, 2026 - Abstract #P3.619; Pres time: Sep 21, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P3; "Management strategies vary and may include withdrawal of CNI therapy, plasma exchange or complement inhibition with drugs like eculizumab...She received induction immunosuppression with anti-thymocyte globulin, followed by standard maintenance therapy: prednisolone, tacrolimus, and mycophenolate mofetil (MMF)...Tacrolimus was subsequently replaced with Belatacept. However, CMV reactivated, necessitating a switch to an mTOR inhibitor (everolimus). Due to concerns for maribavir resistance, valganciclovir was restarted... Delayed post-transplant TMA may be multi-factorial, with contributions from CNI toxicity, viral infections, and genetic mutations. This case highlights the importance of dynamic immunosuppression adjustment and infection management. Ongoing management requires careful balancing of rejection risk and infectious complications, with complement inhibition considered for recurrent or refractory TMA."
Antibody-mediated Rejection • Beta-Thalassemia • Diabetes • Diabetic Nephropathy • Genetic Disorders • Gynecology • Hematological Disorders • Infectious Disease • Metabolic Disorders • Neutropenia • Transplantation • Type 1 Diabetes Mellitus
|
|
Isra Iftikhar1; Anoushka Krishnan1; Rajalingam Sinniah, Germaine Wong2
|